Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Caronia, D; Martin, M; Sastre, J; de la Torre, J; Garcia-Saenz, JA; Alonso, MR; Moreno, LT; Pita, G; Diaz-Rubio, E; Benitez, J; Gonzalez-Neira, A.

A Polymorphism in the Cytidine Deaminase Promoter Predicts Severe Capecitabine-Induced Hand-Foot Syndrome

CLINICAL CANCER RESEARCH. 2011; 17(7): 2006-2013 Nº de citas: 78 [doi:10.1158/1078-0432.CCR-10-1741]

Romero, A; Martin, M; Cheang, MCU; Garcia-Asenjo, JAL; Oliva, B; He, XP; de la Hoya, M; Saenz, JAG; Fernandez, MA; Rubio, ED; Perou, CM; Llopis, TC.

Assessment of Topoisomerase II alpha Status in Breast Cancer by Quantitative PCR, Gene Expression Microarrays, Immunohistochemistry, and Fluorescence in Situ Hybridization

AMERICAN JOURNAL OF PATHOLOGY. 2011; 178(4): 1453-1460 Nº de citas: 73 [doi:10.1016/j.ajpath.2010.12.042]

Valero, V; Forbes, J; Pegram, MD; Pienkowski, T; Eiermann, W; von Minckwitz, G; Roche, H; Martin, M; Crown, J; Mackey, JR; Fumoleau, P; Rolski, J; Mrsic-Krmpotic, Z; Jagiello-Gruszfeld, A; Riva, A; Buyse, M; Taupin, H; Sauter, G; Press, MF; Slamon, DJ.

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

JOURNAL OF CLINICAL ONCOLOGY. 2011; 29(2): 149-156 Nº de citas: 198 [doi:10.1200/JCO.2010.28.6450]

Dieras V; Curigliano G; Martin M; Lerebours F; Tsurutani J; Savard MF; Jerzak KJ; Hu X; Martins de Aquino Pimentel LC; O'Sullivan CC; Tokunaga E; Okines A; Huang CS; Jacot W; Sohn J; Cronemberger Silva E; Mueller V; Yang S; Granata G; Shen Q; Santarpia L; Hamilton E.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

JOURNAL OF CLINICAL ONCOLOGY. ; : [doi:10.1200/JCO-25-02600]